The Eversense 365 implantable continuous glucose monitor (CGM) has launched in Europe. The device is now available to first patients in Sweden, with planned launches in Germany, Spain, and Italy over the coming weeks.
Senseonics says the European rollout is part of its broader growth strategy and could expand its addressable market by more than 30 million patients.
Eversense 365 is the world's first one-year CGM, designed for people with type 1 and type 2 diabetes who are 18 and older. The small sensor is implanted under the skin of the upper arm through a short procedure and works with a removable smart transmitter. It provides glucose readings every five minutes and pairs with a mobile app.
Eversense launched in the U.S. in October 2024. It is currently available alongside the twiist insulin pump in the U.S., which suggests Eversense may be looking into pump partners for its European expansion. While the device continues to grow, the company is also developing its next-generation CGMs, Gemini and Freedom, both of which remove the requirement for an external transmitter.
Want more?
For the latest diabetes tech, join our free newsletter.
If you like our content and want more, join Diabetech All Access—unlocking exclusive Live Q&As, giveaways, stories and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.